Related Experiment Video
Updated: Aug 13, 2026
14:24
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Current treatment and future directions in heart failure
Gretchen Wells1, William C Little
1Cardiology Section, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA.
Current Opinion in Pharmacology
|April 16, 2002
Summary
Current heart failure treatments targeting neurohormonal systems show benefits, but mortality remains high. New research is exploring other pathophysiological pathways to improve outcomes for heart failure patients.
Area of Science:
- Cardiology
- Pathophysiology
- Pharmacology
Background:
- Neurohormonal system activation is a key factor in congestive heart failure pathophysiology.
- Angiotensin-converting-enzyme inhibitors and beta blockers have proven benefits in reducing morbidity and mortality.
- Despite current standard treatments, heart failure mortality rates remain unacceptably high.
Purpose of the Study:
- To review the current understanding of heart failure pathophysiology.
- To highlight the limitations of existing neurohormonal blockade therapies.
- To emphasize the need for investigating novel pathophysiological mechanisms and therapeutic targets.
Main Methods:
- Review of recent clinical trials and research findings in heart failure.
- Analysis of the established benefits of angiotensin-converting-enzyme inhibitors and beta blockers.
- Discussion of emerging research into alternative pathophysiological pathways.
Main Results:
- Established efficacy of angiotensin-converting-enzyme inhibitors and beta blockers in heart failure management.
- Persistent high mortality rates despite guideline-directed medical therapy.
- Identification of the need to explore additional pathophysiological mechanisms beyond neurohormonal blockade.
Conclusions:
- Standard therapies for heart failure, including angiotensin-converting-enzyme inhibitors and beta blockers, are crucial but insufficient.
- Further research into alternative pathophysiological pathways is essential for developing more effective treatments.
- Interruption of newly identified pathways holds promise for reducing heart failure mortality.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...